Related Experiment Video
Updated: Jan 7, 2026

Isolation of Neonatal Extrahepatic Cholangiocytes
Published on: June 5, 2014
Early Metabolic Profile in Neonates with Maternal Intrahepatic Cholestasis of Pregnancy
Bengisu Guner Yilmaz1, Saygin Abali2, Ariorad Moniri3
1Division of Neonatology, Department of Pediatrics, School of Medicine, Acibadem Mehmet Ali Aydinlar University, Istanbul 34638, Turkey.
Insights
Intrahepatic cholestasis of pregnancy (ICP) alters neonatal metabolism, affecting amino acids and fatty acid oxidation. This study highlights potential fetal adaptations to the intrauterine cholestatic environment.
Area of Science:
- Neonatal Metabolism
- Perinatal Medicine
- Biochemistry
Background:
- Intrahepatic cholestasis of pregnancy (ICP) is linked to adverse perinatal outcomes.
- The specific metabolic effects of ICP on newborns are not well understood.
- This study examines metabolic profiles in neonates born to mothers with ICP.
Purpose of the Study:
- To investigate amino acid, carnitine, and acylcarnitine profiles in neonates born to mothers with ICP.
- To characterize neonatal metabolic alterations associated with ICP.
- To identify potential biomarkers for ICP-related neonatal complications.
Main Methods:
- Retrospective analysis of 299 neonates born to mothers with ICP.
- Comparison between ICP-term neonates (n=150) and term controls (n=150).
- LC-MS/MS analysis of capillary blood samples for amino acid and acylcarnitine profiles.
Main Results:
- Elevated levels of certain amino acids (e.g., alanine, leucine/isoleucine) and acylcarnitines observed in ICP-term neonates.
- Decreased levels of other amino acids (e.g., argininosuccinic acid) and acylcarnitines noted in ICP-term neonates.
- Ornithine and leucine/isoleucine showed strong discriminatory potential (AUC > 0.73).
Conclusions:
- Neonatal metabolic profiles in ICP reveal disruptions in amino acid metabolism, fatty acid oxidation, and mitochondrial function.
- These alterations suggest fetal adaptation to the intrauterine cholestatic environment.
- Metabolomic profiling offers insights into maternal-fetal interactions and aids in risk stratification.
Abstract:
Background/Objectives: Intrahepatic cholestasis of pregnancy (ICP) is associated with adverse perinatal outcomes. However, its metabolic consequences on newborns remain inadequately characterized. This study investigated amino acid, carnitine, and acylcarnitine profiles in neonates born to mothers with ICP. Methods: This retrospective study encompassed 299 neonates born to mothers with ICP. For comparative analysis, term infants without additional complications (ICP-term, n = 150) were compared with term controls (n = 150). Capillary blood samples collected at 24-48 h of life as part of newborn screening were analyzed using LC-MS/MS for acylcarnitine and amino acid profiles. Results: The ICP cohort exhibited a high preterm delivery rate (46.2%), with maternal bile acids negatively correlating with gestational age (r = -0.266, p < 0.001). No inborn errors of metabolism were observed. Elevated levels of amino acids (alanine, leucine/isoleucine, valine, tyrosine, arginine, glycine, and ornithine) and specific acylcarnitines (C5, C5-OH, C10:1, and C18:2), along with decreased levels of amino acids (argininosuccinic acid and glutamic acid) and specific acylcarnitines (C3, C5-DC, C6-DC, C14, C14:1, C16, C16:1, and C18:1-OH), were observed in ICP-term neonates (p < 0.05). Receiver operating characteristic curve analysis identified ornithine (area under the curve [AUC] = 0.74) and leucine/isoleucine (AUC = 0.73) as strong discriminators. A multivariable model integrating multiple metabolites achieved high accuracy (AUC = 0.86 ± 0.03). Conclusions: This first comprehensive characterization of neonatal metabolic alterations in ICP reveals amino acid metabolism, fatty acid oxidation, and mitochondrial function disruptions, suggesting fetal adaptation to a cholestatic intrauterine environment. Metabolomic profiling may improve understanding of maternal-fetal interactions and inform strategies for risk stratification and long-term monitoring.
Related Concept Videos
Pharmacokinetics in Pediatric Patients: Drug Metabolism
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
Inborn Errors of Metabolism

